Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213757 · ClinicalTrials.gov registry record · Phase 4
Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)
A Phase 4 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT02213757 is a Phase 4 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 29 participants.
The verdict
NCT02213757, a Phase 4 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if vaginal estrogen use is associated with resolution of blood in the urine (microscopic hematuria) in postmenopausal women. The hypothesis is that postmenopausal women with blood in the urine (microscopic hematuria) will have higher rates of resolution of hematuria after treatment course with vaginal conjugated equine estrogen cream compared to placebo cream
Interventions
- DRUG Placebo vaginal cream
- DRUG Premarin vaginal estrogen cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02213757
The ClinicalTrials.gov registry entry for NCT02213757 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo vaginal cream is the first listed.
NCT02213757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02213757 about?
NCT02213757 is a clinical study titled "Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)". The purpose of this study is to determine if vaginal estrogen use is associated with resolution of blood in the urine (microscopic hematuria) in postmenopausal women. The hypothesis is that postmenopausal women with blood in the urine (microscopic hematuria) will have higher rates of resolution of h...
What is the current status of trial NCT02213757?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2014-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02213757?
The interventions under investigation include: Placebo vaginal cream (DRUG), Premarin vaginal estrogen cream (DRUG).
Who is sponsoring clinical trial NCT02213757?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.